Hypertension (HTN) – Jonathan Davis
Background
- #SBP >20 or #DBP >10 doubles risk of stroke and CVD
- Prevalence ~45% with new cutoff (≥130/80); control achieved in ~50%
- Definitions
- Resistant HTN: Uncontrolled BP despite taking 3 antihypertensive medications including a diuretic, OR 4 total medications
- Whitecoat HTN: Mean BPs lower than threshold of HTN based upon out-of-office measurements (falsely elevated measurements during visits). If SBP > 130 but < 160, consider screening for white coat HTN with home monitoring
- Masked HTN: Mean BP at/above threshold for hypertension based upon out-of-office measurements (falsely decreased measurements during visits). If office SBPs consistently 120-129 consider screening for masked HTN with home monitoring
- Diagnosis
- Requires ≥2 elevated pressures on ≥2 occasions
- Home and ambulatory BP monitoring recommended to confirm diagnosis
- Ideally, measurements with legs uncrossed, arm at level of heart, after 5 minutes of rest and with empty bladder; avoid caffeine or tobacco 30 minutes prior
- Screening
- Grade A USPTF rec: Screen all adults >18. Screen adults at least semiannually if have risk factors for HTN (obesity, AA), or if previously measured SBP 120-129
- Requires ≥2 elevated pressures on ≥2 occasions
ACA-AHA guidelines (2017) (based on SPRINT trial) |
|
Normal |
<120/80 mmHg |
Elevated BP |
systolic 120-129 mmHg AND diastolic <80 mmHg |
Stage 1 |
systolic 130-139 mmHg OR diastolic 80-89 mmHg |
Stage 2 |
systolic ≥140 mmHg OR diastolic ≥90 mmHg |
Evaluation
- BMP, CBC, lipid panel, UA, TSH, EKG. Consider additional testing including TTE, urine Alb:Cr ratio, or uric acid.
- Distinguish between primary (90% incidence) and secondary HTN (10%):
- Suspect 1º if gradual onset, family hx, associated with weight gain & lifestyle factors
- Suspect 2º if early onset (< 30yo), late onset (> 65 y/o), abrupt onset, disproportionate end-organ damage, resistant HTN
- Uncommon causes: Pheochromocytoma, Cushing’s syndrome, thyroid dysfunction, aortic coarctation, primary hyperparathyroidism, acromegaly, congenital adrenal hyperplasia
Common 2o Causes |
Suggestive Feature |
Diagnostic Testing |
Primary Kidney Disease |
Hypervolemia, ↑ Cr, abnormal UA, fhx of PKD |
UA, Urine Alb:Cr ratio, Renal US |
Renovascular disease (RAS or FMD) |
Renal bruit, ↑ Cr after ACE-I or ARB, young age |
Doppler renal US |
OSA |
Apneic events, somnolence, obesity |
Polysomnography |
Primary Hyperaldosteronism |
Hypokalemia, metabolic alkalosis, resistant HTN, etc. |
Start with plasma aldosterone/renin levels |
Drug or Alcohol Induced |
Hx of substance use (cocaine, caffeine, nicotine, medications) |
UDS, BP improvement after withdrawal of suspected agent |
Management
- JNC 8 recommends treating to a goal BP <140/90 in all pts < 60
- Consider intervenable contributing factors:
- Obesity, High Na diet (canned foods, fast foods, processed meats)
- Excess alcohol intake
- Medications (e.g., NSAIDs, decongestants, MAOs, clonidine withdrawal, cyclosporine, steroids)
- Substance use (e.g., caffeine, cocaine, amphetamines)
- Lifestyle interventions (first line for any stage of elevated BP):
- 8-14 mmHg ↓: DASH diet (fresh produce, whole grains, low-fat dairy)
- 5-10 mmHg ↓: Weight loss (10 kg or 22 lbs), expect 1mm Hg for every 1kg reduction in body weight
- 3-9 mmHg ↓: Na+ restriction (1.5 g / day), aerobic exercise for 90-150 min/week, increased intake of K+ rich foods
- 2-4 mmHg ↓:Moderate EtOH (2 drinks/day for men; 1 drink/day for women)
- Medications (See table below):
- Initiate pharmacological therapy with Hypertension Stage I (ACC/AHA guideline) and ASCVD score > 10% or Stage II pts (regardless of ASCVD score)
- Use first line agents from the following classes
- ACE-I or ARB
- Thiazide Diuretics (preferred in AAs)
- Dihydropyridines CCB (preferred in AAs)
Additional Information
VA Specific Guidance: https://www.healthquality.va.gov/guidelines/CD/htn/
- Preferred Agents/Agents that don’t require PADR:
- Diuretics – Any
- ACEIs – Lisinopril, Benazepril, Enalapril, Ramipril, Captopril
- ARBs – Losartan, Valsartan
- Beta Blockers – Carvedilol, Metoprolol tartrate/succinate, atenolol, propranolol
- DHP – Amlodipine
- Non-DHTs – Verapamil, Diltiazem
- Aldosterone Receptor Antagonist – Spironolactone
- Alpha1 Antagonist – Doxazosin, Prazosin, Terazosin
- Direct Acting Vasodilators – Minoxidil, Hydralazine
- Alpha2 Agonist – Clonidine tablet, methyldopa
- Agents that require PADR:
- ACEIs - Quinapril
- ARBs – Candesartan, Irbesartan, Olmesartan, Telmisartan
- Beta blockers – Labetalol, Nebivolol
- DHP – Nifedipine SA
- Aldosterone Receptor Antagonist – Eplerenone
- Alpha2 Agonist – Clonidine patch
- How to get BP cuff at the VA
- Consult tab: New Consult → Select Campus → Select Inpatient or Outpatient → Prosthetics Main
- Consult Menu → Select Y/N for requirement of discharge → BP Cuff TVH
- *Must answer all questions in the consult, including blood pressure cuff size.
Cost:
- Publix: Free (amlodipine, lisinopril), $7.50 x 90 days (losartan, metoprolol tartrate, HCTZ)
- Walmart: $4/month (amlodipine, carvedilol, enalapril, hydralazine, HCTZ, irbesartan, lisinopril, losartan, ramipril)
Drug Class |
Common Drugs |
Side effects/ comments |
Thiazide diuretics |
HCTZ 12.5-50 mg |
- HypoNa, HypoMg, HypoK, increased uric acid, hypovolemia, orthostatic hypotension Ok to use in pregnancy per ACOG (2019), but considered 2nd or 3rd line |
ACE-I |
Lisinopril, benazepril, fosinopril, quinapril (all 5-40 mg daily) Ramipril, 2.5-20 mg in 1-2 doses |
-Angioedema (more common in AA) AKI, hyperkalemia, cough |
ARBs |
Losartan 25-100 mg in 1-2 doses Candesartan 8-32 mg in 1-2 doses Irbesartan 150-300 mg |
-AKI, hyperkalemia (less frequent than ACE-I) |
CCB |
Dihydropyridine:
Nondihydropyridine: Diltiazem ER 120-480 mg Verapamil ER 100-480 mg |
Dihydropyridine:
Nondihydropyridine: |
Aldosterone receptor antagonists |
Spironolactone 12.5-50 mg |
-Good choice for resistant HTN -AKI, hyperkalemia & sexual side effects |
BB |
Carvedilol 6.25-25 mg bid |
Reserve for CHF/CAD |
Vasodilators |
Hydralazine 25-100 mg bid or tid Minoxidil 5-10 mg |
Reflex tachycardia, fluid retention |
Centrally- acting agents (alpha 2 agonists) |
Clonidine 0.1-0.2 qd, (Weekly transdermal patch is preferred to avoid non- compliance and subsequent reflex HTN) Methyldopa 250-500 mg qd |
Rebound hypertension, withdrawal Reserved for resistant hypertension due to unfavorable side effect profile |
Conditions |
Drug Class |
Heart failure |
ACE-I/ARB or ARNI + BB + spironolactone + diuretics |
CAD |
ACE-I or BB |
Diabetes |
All first line agents, ACE-I/ARB if presence of albuminuria |
CKD |
ACE-I/ARB |
Recurrent stroke prevention |
ACE-I, thiazide diuretic |
Pregnancy |
Labetalol (first-line), nifedipine, methyldopa, hydralazine |